ReviewInternational journal of nanomedicine2026
Recent Advances in Nanocarrier-Based Drug Delivery Systems for Lung Cancer.
Review in International journal of nanomedicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Nanocarrier-Based Drug Delivery Systems for Lung Cancer: A Systematic Review and Meta-Analysis of Preclinical Studies.Advances in respiratory medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Lung cancer (LC) remains the leading cause of cancer-related deaths globally. Conventional therapeutic strategies, including surgery, radiotherapy, and chemotherapy, are often hampered by limitations such as poor tumor selectivity, low bioavailability, and severe systemic toxicity, which compromise treatment efficacy. Nanocarriers are colloidal formulations characterized by abundant porosity and unique physicochemical properties, such as tunable size, high specific surface area, and stimuli-responsiveness. Nanocarrier-based drug delivery systems (NDDSs) have emerged as a promising solution to enable targeted delivery, controlled drug release, and theranostics. This review discusses the advantages, limitations, and clinical translation of three major classes of nanodelivery systems for LC therapy: organic, inorganic, and inorganic-organic hybrid nanosystems. Organic systems are characterized by high biocompatibility and versatile drug-loading capacity, whereas inorganic counterparts provide distinctive optical or magnetic functionalities that enable imaging and synergistic therapy. Hybrid designs integrate both material classes to improve stability and therapeutic performance. Future research is expected to focus on optimizing inhalation strategies for deep lung deposition, developing multi-targeted biomimetic carriers, advancing theranostic platforms, and employing computational tools to accelerate nanocarrier design and clinical translation. This review aims to offer critical perspectives on the development and clinical implementation of nanomedicines for LC.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.